These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 17991430

  • 1. The antilipolytic action of bis(alpha-furancarboxylato)oxovanadium(IV) in adipocytes.
    Gao L, Niu Y, Liu W, Xie M, Liu X, Chen Z, Li L.
    Clin Chim Acta; 2008 Feb; 388(1-2):89-94. PubMed ID: 17991430
    [Abstract] [Full Text] [Related]

  • 2. Effects of bis(alpha-furancarboxylato)oxovanadium(IV) on non-diabetic and streptozotocin-diabetic rats.
    Gao LH, Liu WP, Wang BL, Li L, Xie MJ, Li YR, Chen ZH, Chen XZ.
    Clin Chim Acta; 2006 Jun; 368(1-2):173-8. PubMed ID: 16487949
    [Abstract] [Full Text] [Related]

  • 3. [Insulino-mimetic effects of bis (alpha-furancarboxylato) oxovanadium (IV) in vitro].
    Li YR, Gao LH, Ma YL, Niu YF, Liu WP, Li L.
    Yao Xue Xue Bao; 2008 Mar; 43(3):318-22. PubMed ID: 18630272
    [Abstract] [Full Text] [Related]

  • 4. Bis(alpha-furancarboxylato)oxovanadium(IV) prevents and improves dexamethasone-induced insulin resistance in 3T3-L1 adipocytes.
    Zuo YQ, Liu WP, Niu YF, Tian CF, Xie MJ, Chen XZ, Li L.
    J Pharm Pharmacol; 2008 Oct; 60(10):1335-40. PubMed ID: 18812026
    [Abstract] [Full Text] [Related]

  • 5. Effects of bis(alpha-furancarboxylato)oxovanadium(IV) on glucose metabolism in fat-fed/streptozotocin-diabetic rats.
    Niu Y, Liu W, Tian C, Xie M, Gao L, Chen Z, Chen X, Li L.
    Eur J Pharmacol; 2007 Oct 31; 572(2-3):213-9. PubMed ID: 17651728
    [Abstract] [Full Text] [Related]

  • 6. Effect of masoprocol on carbohydrate and lipid metabolism in a rat model of Type II diabetes.
    Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Brignetti D, Luo J, Khandwala A, Reaven GM.
    Diabetologia; 1999 Jan 31; 42(1):102-6. PubMed ID: 10027587
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the antilipolytic effects of an A1 adenosine receptor partial agonist in normal and diabetic rats.
    Dhalla AK, Santikul M, Chisholm JW, Belardinelli L, Reaven GM.
    Diabetes Obes Metab; 2009 Feb 31; 11(2):95-101. PubMed ID: 18494808
    [Abstract] [Full Text] [Related]

  • 8. Effects of new hypoglycemic agent A-4166 on lipolysis and lipogenesis in rat adipocytes.
    Macho L, Fickova M, Zorad S, Sebokova E, Klimes I.
    Endocr Regul; 2000 Sep 31; 34(3):119-26. PubMed ID: 11074662
    [Abstract] [Full Text] [Related]

  • 9. Orally active and long-term acting insulin-mimetic vanadyl complex:bis(picolinato)oxovanadium (IV).
    Sakurai H, Fujii K, Watanabe H, Tamura H.
    Biochem Biophys Res Commun; 1995 Sep 25; 214(3):1095-101. PubMed ID: 7575515
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Bis(α-furancarboxylato)oxovanadium(IV) exerts durable antidiabetic effects and suppresses matrix metalloproteinase-2 activity in spontaneous type 2 diabetic KKAy mice.
    Li L, Gao L, Liu S, Liu Q, Sun S, Huan Y, Li C, Peng J, Hou G, Li L, Liu W, Shen Z.
    Biol Trace Elem Res; 2013 Jun 25; 153(1-3):329-39. PubMed ID: 23649370
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Preparation and characterization of vanadyl complexes with bidentate maltol-type ligands; in vivo comparisons of anti-diabetic therapeutic potential.
    Thompson KH, Liboiron BD, Sun Y, Bellman KD, Setyawati IA, Patrick BO, Karunaratne V, Rawji G, Wheeler J, Sutton K, Bhanot S, Cassidy C, McNeill JH, Yuen VG, Orvig C.
    J Biol Inorg Chem; 2003 Jan 25; 8(1-2):66-74. PubMed ID: 12459900
    [Abstract] [Full Text] [Related]

  • 15. In vivo metabolic effects of naringenin in the ethanol consuming rat and the effect of naringenin on adipocytes in vitro.
    Szkudelska K, Nogowski L, Nowicka E, Szkudelski T.
    J Anim Physiol Anim Nutr (Berl); 2007 Apr 25; 91(3-4):91-9. PubMed ID: 17355338
    [Abstract] [Full Text] [Related]

  • 16. Lack of the effect of mycotoxins-aflatoxin B1 and ochratoxin A on some functions of rat adipocytes.
    Szkudelska K, Drzymała H, Szkudelski T, Bukowska K, Nogowski L.
    Toxicol In Vitro; 2005 Sep 25; 19(6):771-7. PubMed ID: 15963681
    [Abstract] [Full Text] [Related]

  • 17. Possible mode of action for insulinomimetic activity of vanadyl(IV) compounds in adipocytes.
    Kawabe K, Yoshikawa Y, Adachi Y, Sakurai H.
    Life Sci; 2006 May 08; 78(24):2860-6. PubMed ID: 16337244
    [Abstract] [Full Text] [Related]

  • 18. The influence of a new vanadium compound, bis(2,2'-bipyridine)oxovanadium(IV) sulphate on liver golgi complexes from control and streptozotocin-diabetic rats.
    Kordowiak AM, Dabroś W, Kajda B.
    Horm Metab Res; 2002 Oct 08; 34(10):556-60. PubMed ID: 12439783
    [Abstract] [Full Text] [Related]

  • 19. A new orally active antidiabetic vanadyl complex--bis(alpha-furancarboxylato)oxovanadium(IV).
    Xie M, Gao L, Li L, Liu W, Yan S.
    J Inorg Biochem; 2005 Feb 08; 99(2):546-51. PubMed ID: 15621288
    [Abstract] [Full Text] [Related]

  • 20. Effects of lipolytic and antilipolytic agents on glycerol and free fatty acid release from isolated adipocytes of normal and diabetic rats.
    Kamei I, Hotta N, Kakuta H, Kimura M, Fukasawa H, Koh N, Sakamoto N.
    Nagoya J Med Sci; 1989 Mar 08; 51(1-4):17-23. PubMed ID: 2549422
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.